AUTHORS
Clifford Csizmar, M.D., Ph.D., Kristen McCullough, PharmD2, Ian Bouligny, M.D.3, Reza Tabrizi, MD4, Mael Heiblig, MD5, Rami Komrokji, MD6, J. Scott Austin Beeler, MD, PhD7, Aref Al-Kali, M.D.8, Naseema Gangat, MBBS9, Tariq Kewan, MD10, Abhishek Avinash Mangaonkar, MBBS11, Antoine N. Saliba, M.D.12, Alexandre Bazinet, MD, MSc13, Kelly Sharon Chien, MD14, Danielle Hammond, MD15, Courtney DiNardo, MD, MSCE16, Guillermo Garcia-Manero, MD17, Tapan Kadia I, MD18, Rashmi Kanagal-Shamanna, MD19, Sanam Loghavi, MD20, Naveen Pemmaraju, MD21, Farhad Ravandi, MD22, Koji Sasaki, MD, PhD23, Aline Renneville, PhD, PharmD24, Eric Solary, MD25, Najla Al Ali, MS26, Zhuoer Xie, MD,MS27, David Sallman, MD28, Kelly Bolton, MD, PhD29, Eric Padron, MD30, Christophe Willekens, MD31, Guillermo Montalban-Bravo, MD32, Mrinal M. Patnaik, MD, MBBS33
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 CHI de Mont De Marsan, Mont-De Marsan, France
5 Lyon-Sud Hospital, Pierre Bénite, France
6 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
7 Washington University, St. Louis, Missouri, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 Gustave Roussy, Université Paris-Saclay, Villejuif, France
25 Gustave Roussy, Université Paris-Saclay, Villejuif, France
26 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
27 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
28 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
29 Washington University, St. Louis, Missouri, United States
30 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
31 Gustave Roussy, Université Paris-Saclay, Villejuif, France
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
33 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction
IDH inhibitors (IDHi) are approved therapies for IDH1/2-mutated MDS and AML. IDH1/2 mutations occur in 5-7% of CMML cases and are associated with an inflammatory phenotype and poor outcomes (Walsh et al, Leukemia 2022). Despite biologic plausibility and patient (pt)-level evidence of efficacy, off-label access to IDHi for CMML is limited and, given the relative rarity of these alterations, dedicated clinical trials are challenging. This multi-institutional study describes our experience using IDHi in CMML.
Methods
CMML pts treated with an IDHi between 1/1/2016 and 7/1/2026 (data cutoff) at each participating site were included with IRB approval. Pt data were collected at initial diagnosis or first referral to the site. CMML was defined by WHO 5th ed criteria. Responses were assessed using IWG 2006 MDS and IWG 2015 MDS/MPN criteria which yielded concordant classifications.
Results
Twenty-nine pts were identified with median age 72 years (range 45–91). Most were male (86%) and were classified as myelodysplastic (MD)-CMML (54%) and CMML-1 (86%). Approximately one-third of pts were considered high/very high risk by the BLAST-Mol (42%) or iCPSS (29%) prognostic models. IDHi treatment was 1st-line in 15 (56%), 2nd-line in 8 (30%), and ≥3rd line in 4 (15%) pts.
IDH1 mutations were identified in 11 pts and occurred exclusively at R132 with median variant allele fraction (VAF) 40% (range 18–48%). Co-mutations occurred most frequently in ASXL1 (45%), NRAS (36%), and SRSF2 (36%). Five pts were treated with ivosidenib (Ivo) as a single agent. The median duration of therapy (DOT) was 1.5 months (mo; range 0.5–5.4) including 3 pts continuing on treatment. The overall response rate (ORR) was 40%, with 2 pts achieving hematologic improvement (HI); a third achieved stable disease (IWG 2006) with symptom benefit (IWG 2015). Five pts were treated with Ivo plus azacitidine (Ivo-Aza) for a median DOT of 4.8 mo (range 2.5–45) including 2 pts continuing. The ORR was 100% including 4 complete responses (CR) and 1 marrow CR. One pt was treated with Ivo plus venetoclax (Ivo-Ven) for 9.5 mo and achieved a CR. One pt who progressed on Ivo subsequently received olutasidenib plus decitabine (Olu-Dec) without response.
IDH2 mutations were identified in 18 pts and occurred exclusively at R140 with median VAF 40% (range 7–48%). Co-mutations occurred most frequently in SRSF2 (83%), ASXL1 (44%), and KRAS (39%). Thirteen pts were treated with single-agent IDH2i (enasidenib [Ena], n=12; vorasidenib [Vor], n=1). The median DOT was 3.7 mo (range 0.5–73) including 2 pts continuing. The ORR was 46% with 6 pts achieving HI; 4 additional pts achieved stable disease (IWG 2006). Five pts were treated with Ena plus a hypomethylating agent (Ena-Aza, n=3; Ena-Dec/cedazuridine, n=2) for a median DOT of 3.6 mo (range 1.0–13) including 1 pt continuing. The ORR was 80% including 1 CR, 1 marrow CR, and 2 HI.
After median follow-up of 44 mo, the median overall survival (mOS) for the cohort was 36 mo (95% confidence interval [CI] 28–not reached [NR]) and was not different for IDH1 vs IDH2 mutated cases (p=0.46). The mOS for those treated with single-agent IDHi was 34 mo (95% CI 26-NR) and was similar for responders vs non-responders (36 vs 28 mo, p=0.18). The mOS for those treated with an IDHi-based doublet was 68 mo (95% CI NR–NR) and was improved for responders vs non-responders (68 vs 4 mo, p=0.046). There was no association between IDH1/2 VAF or co-mutation status and OS. Two pts proceeded to allogeneic stem cell transplant, one treated with Ena and one with Ivo-Aza. Six (21%) pts experienced differentiation syndrome including 2 grade 1, 2 grade 2, 1 grade 3, and 1 grade 5 event in a pt treated with single-agent Ivo.
In the Mayo cohort (n=10), 6 pts had concurrent autoinflammatory symptoms. Three pts (50%) had symptom improvement after starting IDHi therapy, including 1 pt with complete resolution.
Conclusions
In this largest reported series of IDH1/2-mutated CMML treated with IDHi, IDHi demonstrated clinical activity comparable to that reported in MDS and AML. IDHi-based combination therapy produced deeper and more durable responses, while differentiation syndrome remained an important but manageable toxicity. These findings support prospective evaluation of IDHi-based strategies in CMML and provide real-world evidence to inform future treatment recommendations.
DISCLOSURES
Clifford Csizmar, M.D., Ph.D.: No relevant conflicts of interest to declare.